Copyright
©The Author(s) 2022.
World J Clin Cases. May 16, 2022; 10(14): 4380-4394
Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4380
Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4380
Table 4 Univariate analysis of the general information of patients in the high and the low neutrophil-lymphocyte ratio group
| Characteristic | NLR < 3 (n = 56) | NLR ≥ 3 (n = 26) | P value |
| Age (yr) | 60.93 ± 9.88 | 59.04 ± 9.10 | 0.411 |
| Gender, n (%) | 0.981 | ||
| Male | 30 (53.6) | 14 (53.8) | |
| Female | 26 (46.4) | 12 (46.2) | |
| ISS stage, n (%) | 0.693 | ||
| ISS-I | 10 (17.9) | 5 (19.2) | |
| ISS-II | 27 (48.2) | 10 (38.5) | |
| ISS-III | 19 (33.9) | 11 (42.3) | |
| Number of lesions, n (%) | 0.033a | ||
| 1 | 41 (73.2) | 12 (46.2) | |
| 2 | 8 (14.3) | 10 (38.5) | |
| ≥ 3 | 7 (12.5) | 4 (15.4) | |
| Site of lesion, n (%) | 0.982 | ||
| Spine | 38 (67.9) | 18 (69.2) | |
| Long bone of limb | 13 (23.2) | 6 (23.1) | |
| Soft tissue | 5 (8.9) | 2 (7.7) | |
| Time from a diagnosis to surgery (mo) | 21.18 ± 29.75 | 15.81 ± 18.44 | 0.321 |
| Preoperative nutrition, n (%) | 0.071 | ||
| Well | 50 (89.3) | 18 (69.2) | |
| Fairly | 3 (5.4) | 3 (11.5) | |
| Poorly | 3 (5.4) | 5 (19.2) | |
| Preoperative BMI (kg/m2) | 23.80 ± 3.29 | 21.74 ± 3.13 | 0.009a |
| Preoperative performance status, n (%) | 0.066 | ||
| Grade 0-2 | 14 (25.0) | 2 (7.7) | |
| Grade 3-4 | 42 (75.0) | 24 (92.3) | |
| MM activity at the time of surgery, n (%) | 0.590 | ||
| Partial response | 2 (3.6) | 0 (0.0) | |
| Stable disease | 5 (8.9) | 3 (11.5) | |
| Progressive disease | 49 (87.5) | 23 (88.5) | |
| Preoperative chemotherapy, n (%) | 0.707 | ||
| Yes | 32 (57.1) | 16 (61.5) | |
| No | 24 (42.9) | 10 (38.5) | |
| Preoperative chemotherapy regimens (n = 48), n (%) | 0.216 | ||
| Immunomodulator-based | 6 (37.5) | 5 (15.6) | |
| Proteasome inhibitor-based | 6 (37.5) | 14 (43.8) | |
| Both immunomodulator and proteasome inhibitor | 4 (25.0) | 13 (40.6) | |
| Postoperative chemotherapy, n (%) | 0.080 | ||
| Yes | 51 (91.1) | 20 (76.9) | |
| No | 5 (8.9) | 6 (23.1) | |
| Postoperative chemotherapy regimens (n = 71), n (%) | 0.159 | ||
| Immunomodulator-based | 3 (6.0) | 4 (19.0) | |
| Proteasome inhibitor-based | 17 (34.0) | 4 (19.0) | |
| Both immunomodulator and proteasome inhibitor | 30 (60.0) | 13 (61.9) | |
| Autologous stem cell transplantation, n (%) | 0.458 | ||
| Yes | 15 (26.8) | 5 (19.2) | |
| No | 41 (73.2) | 21 (80.8) | |
| POS (mo) | 32.68 ± 21.76 | 14.86 ± 14.28 | 0.001 |
- Citation: Xu ZY, Yao XC, Shi XJ, Du XR. Significance of preoperative peripheral blood neutrophil-lymphocyte ratio in predicting postoperative survival in patients with multiple myeloma bone disease. World J Clin Cases 2022; 10(14): 4380-4394
- URL: https://www.wjgnet.com/2307-8960/full/v10/i14/4380.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i14.4380